Exelixis, Bristol-Myers cancer deal

EXEL and BMY partnered to discover, develop and commercialize small molecules against mutually selected, undisclosed cancer targets. EXEL will

Read the full 194 word article

How to gain access

Continue reading with a
two-week free trial.